Propranolol-Induced Lethargy
Mechanism and Presentation
- Propranolol is a non-selective beta-blocker that crosses the blood-brain barrier due to its lipophilic properties, which contributes to its central nervous system effects, according to the American College of Cardiology 2
Evidence from Guidelines and Drug Labeling
- The European Heart Journal guidelines identify lethargy as one of the most common reported adverse symptoms of beta-blockers, including propranolol, with a focus on patients with reduced hepatic clearance 1
- In pediatric patients treated for infantile hemangiomas, lethargy is recognized as a potential manifestation of neuroglycopenia (related to hypoglycemia) that can occur with propranolol therapy, as noted by the American Academy of Pediatrics 3, 4, 5
Risk Factors and Associated Symptoms
- Lethargy may be more pronounced in elderly patients, as indicated by the American College of Cardiology 2
- Patients with reduced hepatic clearance are at increased risk of lethargy, according to the European Heart Journal guidelines 1
Clinical Implications and Management
- If a patient develops significant lethargy on propranolol, consider dose reduction if the therapeutic effect can be maintained, as recommended by the European Heart Journal 1
- Evaluate for hypoglycemia, especially in pediatric patients or those with restricted oral intake, as advised by the American Academy of Pediatrics 3, 4, 5
- Consider switching to a less lipophilic beta-blocker that has reduced blood-brain barrier penetration, as suggested by the American College of Cardiology 2